Last reviewed · How we verify
Cytos Biotechnology AG — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
0 Phase 3
5 Phase 2
2 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
Therapeutic area mix
- Autoimmune diseases · 1
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Astellas Pharma Global Development, Inc. · 1 shared drug class
- Barbara Ensoli, MD · 1 shared drug class
- Bharat Biotech International Limited · 1 shared drug class
- Chiang Mai University · 1 shared drug class
- Clinical Research Organization, Dhaka, Bangladesh · 1 shared drug class
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- ANRS, Emerging Infectious Diseases · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Cytos Biotechnology AG:
- Cytos Biotechnology AG pipeline updates — RSS
- Cytos Biotechnology AG pipeline updates — Atom
- Cytos Biotechnology AG pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Cytos Biotechnology AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cytos-biotechnology-ag. Accessed 2026-05-16.